Lataa...
1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
BACKGROUND: ME1100 (arbekacin inhalational solution) is an inhaled aminoglycoside being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). PK-PD target attainment analyses were undertaken to evaluate ME1100 regimens for pat...
Tallennettuna:
| Julkaisussa: | Open Forum Infect Dis |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6252562/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1223 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|